Evidence map›Paper›PMID 40920483›Full record

ReviewClinical journal of the American Society of Nephrology : CJASN2026

Optimizing Dialysis Vascular Access: Moving beyond Fistula First.

Michael Allon, Carlton J Young, Timmy Lee

Abstract readReview
In one paragraph

Review in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael AllonDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
Carlton J YoungDivision of Transplant Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Timmy LeeDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0002-5305-7268

Funding

Barriers to arteriovenous fistula use in black hemodialysis patientsR01MD013818 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLON, MICHAEL · 2019 to 2023
$2.3M
NIMHD NIH HHS 1R01MD013818-01NIMHD NIH HHS R01 MD013818
6 · The paper itself

Abstract

For many years, the vascular access guidelines recommended placement of arteriovenous fistulas (AVFs) in preference to arteriovenous grafts (AVGs) because AVFs had superior long-term patency, required fewer interventions to maintain patency, and were associated with lower costs of vascular access management. However, subsequent research has questioned the Fistula First strategy (placing an AVF whenever the vascular anatomy is suitable). First, AVF nonmaturation is substantial (30%-40%) and even higher among women, older patients, and those with peripheral vascular disease. Second, about half of AVFs require surgical or percutaneous interventions to assist maturation. Moreover, AVFs that require assisted maturation have shorter patency and require more frequent interventions, as compared with AVFs with unassisted maturation. Third, in an intent-to-treat analysis, when the Fistula First strategy is followed in patients initiating hemodialysis with a central venous catheter, the annual frequency of access procedures and the overall cost of access management are substantially greater for AVFs than AVGs. Fourth, in patients with advanced CKD undergoing predialysis access AVF rather than AVG placement, initiation of dialysis with a central venous catheter is much more common. An alternative strategy is a more selective one, in which patients at high risk of AVF nonmaturation preferentially receive an AVG, even if the vascular anatomy is suitable for an AVF. As compared with the Fistula First strategy, the more selective vascular access strategy is associated with fewer access procedures and a lower annual cost of access management. In summary, a more nuanced, patient-centered approach to vascular access may improve access outcomes, decrease the burden of access procedures, and lower the overall costs of vascular access management. This realization has been distilled in the 2019 updated Kidney Disease Outcomes Quality Initiative Vascular Access Guidelines, which exhort nephrologists and surgeons to place the right access in the right patient at the right time for the right reason.

Indexed as

Arteriovenous Shunt, SurgicalBlood Vessel Prosthesis ImplantationRenal DialysisGraft Occlusion, VascularHumansVascular Patencyarteriovenous accessarteriovenous fistulaarteriovenous graft

Identifiers

PMID40920483
PMCPMC12959745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.